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Resveratrol, a compound enriched in red grape skin, has 
been reported to increase lifespan in yeast, worms and 
flies and enhance healthspan in rodents. Beneficial 
effects of resveratrol have been reported in aging-
related cataracts, bone loss, neurodegeneration, obesity 
and diabetes. Resveratrol induces multiple genes 
expression mimicking caloric restriction (CR), which is 
the most conserved longevity-promoting manipulation 
across species [1]. Resveratrol intake conferred 
metabolic changes similar as CR in obese individuals 
[2]. Short-term consumption of resveratrol achieved a 
similar effect of CR [3]. In 2004, David Sinclair’s group 
from Harvard Medical School in Boston identified 
resveratrol for the first time as a “direct” activator of 
SIRT1 using a fluorophore-conjugated synthetic peptide 
as targets [4]. SIRT1 is a NAD+-dependent protein 
deacetylase and regulates various metabolic pathways. 
Loss of SIRT1 abolishes many beneficial effects of CR, 
while transgenic mice with additional copies of SIRT1 
show phenotypes resembling CR [5]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Over the past several years, CR-mimicking properties of 
resveratrol and SIRT1 have attracted considerable 
efforts in searching for resveratrol mimics. Based on the 
same screening strategy, researchers in Sirtris 
Pharmaceuticals found more than 5,000 SIRT1-
activating compounds (STACs). One of the most 
characterized is SRT1720, which exhibits more than 
1000-fold increase in SIRT1-activating potential  compar- 
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ed with resveratrol and elicits similar CR-mimicking 
beneficial effects as resveratrol does [6]. However, in 
2005, two independent groups reported that resveratrol 
only specifically enhances SIRT1 activity towards the 
fluorophore-conjugated rather than the unmodified 
synthetic peptide. This notion was later confirmed by 
other independent groups, showing that resveratrol and 
SRT1720 do not confer any SIRT1 activation towards 
its full-length native target proteins, including p53 and 
PGC-1α [7]. Although whether and how resveratrol 
activates SIRT1 remain unclear, many of its in vivo 
benefits have been shown to be dependent on SIRT1. 
 
In the current issue of Cell Metabolism (Volume 16, 
Issue 6, 738-750, 5 December 2012), we reported 
thatlamin A directly binds to SIRT1 and serves as an 
endogenous activator of SIRT1. Resveratrol treatment 
activates SIRT1 in vivo, ameliorates progeroid features 
and extends lifespan in a Hutchinson-Gilford progeria 
syndrome (HGPS) mouse model, Zmpste24 null mice. 
Lamin A, encoded by the LMNA gene, is a major 
component of the nuclear lamina and nuclear matrix, a 
filamentous nucleoskeleton critical for maintenance of 
nuclear structure. In HGPS cells where substantial 
amount of lamin A is replaced with progerin [8], SIRT1 
deacetylase activity was significantly reduced due to 
decreased association of SIRT1 with nuclear matrix. In 
vivo and in vitro experiments revealed that the binding 
of lamin A to SIRT1 protein is critical to SIRT1 
activation. As only lamin A but not lamin C interacts 
with SIRT1, the C-terminal specific domain of lamin A 
is most likely responsible for the interaction; and the 
farnesylated carboxyl tail in progerin and prelamin A 
might interfere with the interaction as well as the 
activation of SIRT1. Although how resveratrol activates 
SIRT1 is still unclear, it is likely that the binding of 
lamin A with SIRT1 has an allosteric effect on SIRT1 
conformation which exposes active site of SIRT1 
deacetylase to it native substrates. In an effort to further 
investigate whether lamin A serves as a co-factor of 
resveratrol in the activation of SIRT1, we found that 
resveratrol alone does not activate SIRT1 towards its 
native target, e.g. full-length acetyl p53. Instead, 
resveratrol enhances the binding of SIRT1 to lamin A 
and thus increases SIRT1 deacetylase activity. One 
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possible explanation is that resveratrol might modulate 
the SIRT1 conformation, thus increasing the binding of 
SIRT1 to lamin A and enhancing its deacetylase 
activity. An alternate explanation could be that 
resveratrol bridges new interacting domains of lamin A 
and SIRT1. In any case lamin A might serve as an 
allosteric effector of SIRT1. Given that the C-terminal 
80 amino acids of lamin A exhibits higher potential in 
activating SIRT1, it is also possible that the remaining 
part of lamin A might impose a conformational barrier 
for SIRT1 activation, and resveratrol might lead to 
allosteric changes in the lamin A-SIRT1 complex and 
thus further activate SIRT1. Nevertheless, the present 
finding provides direct evidence that resveratrol works 
through Lamin A in activating SIRT1 and suggests a 
therapeutic strategy based on SIRT1 pathway for 
HGPS. Also provided is a screening strategy for SIRT1-
activating/inhibiting compounds based on the 
interaction between lamin A and SIRT1 and SIRT1-
activating property of lamin A. Since the increase in 
SIRT1 deacetylase activity also confers beneficial 
effects on various mouse models mimicking human 
metabolic or degenerative diseases, such as obesity, 
diabetes and Alzheimer Diseases, SIRT1-activating 
compounds could benefit human patients suffering from 
various metabolic and aging-related degenerative 
diseases. On the other hand, SIRT1 protein is found 
upregulated in various human cancers and SIRT1-
inhibiting compounds can be used to treat human 
malignancies. 
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